
The episode discusses Neion Bio's innovative approach to drug manufacturing using genetically engineered chicken eggs.
What happens when an evolutionary biologist and an aerospace engineer both arrive at the same conclusion — that the future of drug manufacturing isn't steel, it's biology? In this episode, Karl Schmieder and Erum Azeez Khan sit down with Sam Levin (Co-Founder & CTO) and Dimi Kellari (Co-Founder & CEO) of Neion Bio to unpack one of the most counterintuitive ideas in modern biomanufacturing: producing therapeutic medicines inside genetically engineered chicken eggs. Rather than optimizing the same mammalian cell culture systems that have defined biopharma for 50 years, Neion Bio's Raptor platform replaces complex steel bioreactor infrastructure with a self-replicating, two-input biological system — chicken feed and water in, life-saving medicines out. The conversation covers their stealth-to-commercial journey, a multi-product monoclonal antibody partnership announced alongside $11M in seed funding, the scalability and supply chain resilience advantages of egg-based manufacturing, how they navigate FDA regulation with a living bioreactor, and their North Star: dropping end-to-end production costs of monoclonal antibodies below $10 per gram — an order of magnitude that could…
Hosts: Karl Schmieder, Erum Azeez Khan
Guests: Sam Levin, Dimi Kellari
Organizations: Neion Bio, FDA
Explore listener stats, chart rankings, contacts and more on the Grow Everything Biotech Podcast podcast page.